Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2015 | 1 |
2016 | 1 |
2018 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11.
Leukemia. 2019.
PMID: 30206306
No abstract available.
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.
Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D.
Silacci M, et al. Among authors: attinger toller i.
MAbs. 2016;8(1):141-9. doi: 10.1080/19420862.2015.1093266. Epub 2015 Sep 22.
MAbs. 2016.
PMID: 26390837
Free PMC article.
Clinical Trial.
Item in Clipboard
A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.
Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, Grabulovski D.
Brack S, et al. Among authors: attinger toller i.
Mol Cancer Ther. 2014 Aug;13(8):2030-9. doi: 10.1158/1535-7163.MCT-14-0046-T. Epub 2014 Jul 3.
Mol Cancer Ther. 2014.
PMID: 24994770
Item in Clipboard
Cite
Cite